Skip to main content
INTS logo

INTS · Intensity Therapeutics, Inc.

Track INTS — free
$3.08 -0.02 (-0.65%) At close · Nov 13
Market Cap
$10.17M
Shares
3.30M
Volume · Nov 13 25.63K Avg daily vol (3M) 22.95K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.08 Open$3.06 Day$2.92–3.09 52W close$3.00–14.75 Avg vol 30d20K Short int76K · 2.3% of shares · 7.2d Short vol15% Last earningsNov 5, 2026 DataJun 2023–Nov 2026 Filing10-Q · Nov 5

Up next

Dec 31, 2026 Scheduled · in 6 wks

Latest documents

2026
Nov 5
Earnings call
Enrollment resumes as capital constrains trial expansion

Intensity Therapeutics resumed patient enrollment in Invincible III and Invincible IV, while capital remained the gating factor for Invincible III activation and enrollment speed. Cash and equivalents were $8.5 million as of September 30, 2026.

5 source passages
Good morning, and welcome to the Intensity Therapeutics third quarter 2026 financial results conference call. In the current year quarter, we resumed new patient enrollment activities in the Invincible III study in a limited number of U.S. sites after pausing new site activations and patient enrollment in March 2025 due to funding constraints. Our clinical trial expenses also included $104,000 for our Phase II Invincible IV study, which also resumed patient enrollment and treatment. So, capital will be the gating factor on how quickly we enroll. As of September 30, 2026, we had cash and cash equivalents of $8.5 million. Open the document at this passage
Nov 5
Current report 8-K
Enrollment Resumes in Two Trials; Cash Stand at $8.5 Million

Intensity Therapeutics reported enrollment resumed in INVINCIBLE-3 and INVINCIBLE-4 during the third quarter of 2026. Cash and cash equivalents were $8.5 million as of September 30, 2026, while third-quarter net loss was $3.5 million.

Financial results
5 source passages
New patient enrollment activities resumed in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study in the third quarter of 2026 New patient enrollment and treatment resumed in the presurgical triple negative breast cancer (“TNBC”) Phase 2 INVINCIBLE-4 Study in the third quarter of 2026 Cash and cash equivalents of $8.5 million as of September 30, 2026 Net loss was $3.5 million for the third quarter of 2026, compared with a net loss of $2.7 million for the third quarter of 2025. SHELTON, Conn., November 5, 2026 – Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces third quarter 2026 financial results and provides a business update. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Enrollment resumes as going-concern doubt persists

Intensity Therapeutics resumed INVINCIBLE-3 enrollment in the third quarter of 2026, while INVINCIBLE-4 data showed 71% pCR versus 42% for SOC. Cash was $8.5 million and nine-month net loss was $9.0 million, raising substantial going-concern doubt.

Net loss $3.54M Diluted EPS -$1.09
Read from the MD&A section
8 source passages
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. In July 2024, we initiated and dosed our first patient in a Phase 3 open-label, randomized study (the “INVINCIBLE-3 Study”) testing INT230-6 as a monotherapy compared to the standard of care (“SOC”) drugs in second- and third-line treatment for certain soft tissue sarcoma subtypes. In October 2024, in collaboration with the Swiss Cancer Institute (“SCI”), formerly the Swiss Cancer Group for Clinical Cancer Research (SAKK), we initiated and dosed our first patient in a Phase 2 study (the “INVINCIBLE-4 Study”) to treat patients with localized triple-negative breast cancer. New patient enrollment activities resumed in the third quarter of 2026. Preliminary data from the first 14 patients (seven in each cohort) showed a 71% pCR in patients receiving INT230-6 in Cohort A and a 42% pCR in patients receiving the SOC alone (Cohort B). As of September 30, 2026, our cash and cash equivalents were approximately $8.5 million. We incurred net losses of $9.0 million and $8.6 million for the nine months ended September 30, 2026 and 2025, respectively. As a result, we believe there is substantial doubt about our ability to continue as a going concern. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$12.04M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$8.49M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+89.2%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
2.3%
Latest settlement · 7.2 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Enrollment resumed in both INVINCIBLE-3 and INVINCIBLE-4, and preliminary INVINCIBLE-4 data showed higher pathological complete response and fewer grade 3 and immune-related adverse events with INT230-6 than with standard of care alone. Net loss increased 33%, operating cash burn is expected to rise, full enrollment remains dependent on capital, and resolution of the revised dosing regimen’s skin issue awaits an independent safety review.

Bullish
  • + Two clinical manuscripts were accepted for peer review, and management reported continuing interest from potential business-development partners. new
  • + A new INT230-6 manufacturing batch is expected to be completed in the first quarter of 2027 and is likely to supply both ongoing clinical studies. new
  • + INVINCIBLE-3 adopted CHOI density-based response criteria to better assess progression while retaining overall survival as the endpoint. new
Bearish
  • − INVINCIBLE-3 patients had not yet been randomized as of the earnings call. new
  • − Full INVINCIBLE-3 enrollment and site activation remained contingent on sufficient incremental funding. new
  • − Resolution of the localized skin irritation under the revised INVINCIBLE-4 dosing regimen remained unconfirmed pending an independent safety review expected in the first quarter of 2027. new
  • − The new INT230-6 manufacturing batch incurred $162,000 in higher manufacturing costs. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −37%
below
Price vs 50-day avg −13%
below
RSI (14) 42
neutral
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −8%
trailing
6-month return −34%
trailing
YTD return −70%
this year
Relative strength −35%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Accumulating
17 of 16 funds reported for Sep 30 · net +202.3K sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.30% of shares out · ▼ -13.6% MoM · 7.2 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
16 holders — mid 3-yr range
Squeeze score 49
elevated · 0–100
Fundamentals
Excellent
EPS growth +71%
Y/Y
Balance sheet $11.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 78%
annualized · 1-yr
Max drawdown −80%
past year
ATR 9.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 11, 2026
second half of 2026
Operating cash burn $1M
the next several years
Incremental capital required to complete the Invincible 3 study $30M
Incremental capital to complete the Invincible 3 study $30M
the balance of 2026
Monthly cash burn $1M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−37% Bearish
Price vs 50-day avg
−13% Bearish
RSI (14)
42 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Accumulating
17 of 16 funds reported for Sep 30 · net +202.3K sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.30% of shares out · ▼ -13.6% MoM · 7.2 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
16 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $3 · 1% Range high $15
vs 200-day avg -37% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
INTS
Intensity Therapeutics, Inc.
this stock
$10.17M — — — 2.3%
VRTX
Vertex Pharmaceuticals Inc
$136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
$90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
$66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
15
% held
26.5%
Reported
17 of 16
Top holder
Kingsbury Capital Investm…
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Falling
Shares short
75.9K
Days to cover
7.2d
Change
-11.9K sh
View
Short Volume
Short vol %
15%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
3.6K
Value
$12.7K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
66.3%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-11.6M
EPS diluted
$-8.56
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 5, 2026
This year
18

Intensity Therapeutics reported enrollment resumed in INVINCIBLE-3 and INVINCIBLE-4 during the third quarter of 2026. Cash and cash equivalents were $8.5 million as of September 30, 2026, while third-quarter net loss was $3.5 million.

View
Exempt Offerings
Offering
$3.6M
Filed
Dec 5, 2024
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 31, 2026
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Intensity Therapeutics Reports Th…
Published
Nov 5, 2026
Upcoming events
3
View

Performance

5D 20D 120D MTD YTD
INTS +2.7% -8.1% -34.2% -9.4% -70.0%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +0.1% -6.9% -34.7% -9.2% -80.6%
Key facts CIK 1567264 CUSIP 45828J202 13F (30d) 13 filings 13 filers Visit website Investor relations